Background. Acute rejection (AR) and development of chronic rejection, bronchiolitis obliterans syndrome (BOS) remain major limiting factors for lung transplantation (LTx). This retrospective study is to identify differentially expressed circulating microRNAs (miRNAs) that associate with development of AR and BOS in pediatric lung transplant recipients (LTxR). Methods. We determined the circulating levels of 7 selected candidate miRNAs in 14 LTxR with AR, 7 with BOS, and compared them against 13 stable pediatric LTxR at 1, 6, and 12 months after LTx. In addition, 6 AR, 7 BOS, and 8 stable pediatric LTxR, 16 AR, 17 BOS, and 16 stable adult LTxR were included for validation. Results. were significantly lower in AR and miR-144, -142-5p, -155 were higher in AR compared to stable (P < 0.05). In addition, circulating levels of miR-134, -10a, -195, -133b were significantly lower and miR-144, -142-5p, -155 were higher (P < 0.05) with development of BOS. The receiver-operating characteristic demonstrated that miR-142-5p, miR-155, and miR-195 strongly discriminated patients with AR from stable LTxR (P < 0.001 for all comparisons): miR-142-5p (area under the curve [AUC], 0.854), miR-155 (AUC, 0.876), and miR-195 (AUC, 0.872). Further, miR-10a, miR-142-5p, miR-144, and miR-155 strongly discriminated BOS from stable LTxR (P < 0.001 for all comparisons). Conclusions. We demonstrated that differential expression of circulating miRNAs occurs in LTxR with AR and BOS, suggesting that they can provide not only important clues to pathogenesis but also may serve as potential noninvasive biomarkers for AR and BOS after pediatric LTx.
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(Transplantation 2017;101: 2461-2468) C hronic allograft rejection, manifested histopathologically as obliterative bronchiolitis, 1 is the single largest contributor to morbidity and mortality after lung transplantation (LTx), affecting up to 50% to 60% of patients who survive to 5 years after undergoing transplant. 2 Acute rejection (AR) occurs in 30% to 50% of lung transplant recipients (LTxR) and is considered as the leading alloimmunedependent risk factor for bronchiolitis obliterans syndrome (BOS). 3, 4 Although the onset of BOS can occur 1 or 2 years posttransplant, there are no diagnostic methods available during early posttransplant period. Therefore, there is a clear and urgent need to explore and develop new options for the early evaluation of patients at risk of AR and BOS after LTx.
MicroRNAs (miRNAs) have recently emerged as relevant factors in organ rejection because of their capacity to regulate a number of target genes that are key elements of both innate and adaptive immune responses. [5] [6] [7] Anglicheau et al 8 reported that miR-10a, -10b, 30c, 32, 142-3p, -223, and let7c were aberrantly regulated in allograft biopsies undergoing AR in renal transplant recipients compared with those in stable allograft. miR-326, -142-5p, -101, -144, -27a, -424, and -339-3p were increased in liver 9 and heart 10 transplant patients during AR. Recently, our group demonstrated that there were 74 miRNAs upregulated and 6 miRNAs downregulated in LTxR with BOS when compared to stable, 11 including miR-369-5p, miR-548d, miR-628-5p, and miR-134. miRNAs are known to be highly stable in serum 12 and urine, 13 making them potential biomarkers for rejection status of solid organ allografts. However, at present, there lacks functional evidences showing miRNAs are dysregulated in the serum of lung allografts with AR and BOS. The current study is to characterize the differentially expressed miRNAs in serum from pediatric LTxR and to define their impact on the development of AR and BOS after LTx.
MATERIALS AND METHODS
This study was approved by the Washington University Human Studies Committee, and all patients were enrolled following informed consent.
Patient Selection
Forty-eight pediatric LTxR were selected from 7 academic medical centers that are members of the Clinical Trials in Organ Transplantation in Children (CTOTC-03) (Children's Hospital of Boston, Nationwide Children's Hospital, Baylor College of Medicine/Texas Children's Hospital, Washington University School of Medicine/St. Louis Children's Hospital, Children's Hospital of Philadelphia, Lucile Packard Children's Hospital at Stanford). Among these patients included, 20 had a diagnosis of biopsy-proved AR, and had no evidence of BOS 2 years after LTx (AR group); 7 were clinically diagnosed as BOS patients (BOS group) and 21 didn't develop AR and BOS (stable group). For the discovery pilot study, 14 AR, 7 BOS, and 13 stable patients were selected, and serum was collected at 1, 6, and 12 months after LTx (Table 1, Figure 1A ). The pediatric subjects and samples for the discovery study were chosen as described in flowchart ( Figure S1A , SDC, http://links.lww.com/TP/B380). Within AR group, all 14 patients developed AR in 1 month (1.1 ± 0.3) after LTx, and successfully treated with no evidence of AR at 6 (5.9 ± 0.9) and 12 (12.3 ± 2.2) months after LTx. Further, these patients did not have any evidence for BOS. All of the 7 patients with BOS developed BOS at 12 months after LTx. All 13 stable patients maintained normal graft function at 1-year posttransplant. All biopsies were graded for rejection according to standard International Society for Heart and Lung Transplantation criteria.
14 LTxR from the 3 groups of both discovery and validation studies were matched for ages, primary diseases, type of LTx, time from transplantation to index biopsy. All pediatric patients were treated with standard immunotherapy as tacrolimus, mycophenolate mofetil, and prednisone at baseline. All centers followed a uniform protocol for treatment of rejection ( Table S1 , SDC, http://links.lww.com/TP/B380). There was no significant difference in PBMC cell number (per ml blood) between stable, AR, and BOS groups. We did not count the T, B cells separately. There were no patients with infection or treated with antibiotics at or before the sampling time points. All the patients had conventional graft histopathology together with concomitant assessment of miRNA expression in the allograft and serum taken at the time of biopsy. For validation, an independent cohort of 8 stable and 6 AR patients were enrolled, as well as 7 samples from different visit points of the same BOS cohorts because of limited pediatric BOS patients (Table S2, Table S3 , SDC, http://links.lww.com/TP/B380). The diagnosis of BOS was made by the criteria established by the International Society for Heart and Lung Transplantation. 2 The immunosuppressive regimen was composed of tacrolimus, mycophenolate mofetil, and prednisone.
TaqMan miRNA Assay for Individual miRNAs
Total serum RNA including small RNAs was isolated using Qiagen miRNeasy Serum/Plasma Kit (Qiagen, Valencia, CA) according to the manufacturer's recommendations. In addition, 1 μg MS2 RNA as carrier RNA (Roche) was added during RNA purification steps to maximize the RNA yield and minimize purification efficiency variation. Individual miRNA analysis were performed using TaqMan miRNA assays (Applied Biosystems, Foster City, CA) as previously described. 11 A synthetic RNA spike-in, Caenorhabditis elegans miR-39 miRNA mimic, was added before cDNA synthesis as a control for variation in reverse transcription efficiency. The PCR amplifications were carried out by incubation for 10 minutes at 95°C, followed by 40 amplification cycles at 95°C for 10 seconds and 60°C for 1 minute. All reactions were performed in duplicate. A cutoff for unspecific amplification was set at the cycle threshold (C t ) = 35. miRNA with more than half of the C t values greater than 35 per group were excluded from the analysis. The spike-in amplification values was used for quality control of each sample. Because U6 RNA and 5S rRNA are degraded in sera and a consensus and miR-130a. 19 Statistical Analysis
Demographics and clinical characteristics of pediatric LTx patients
We applied a 2-stage screening strategy ( Figure 1B ). In the prescreening stage for the cross-sectional study, longitudinal data with the linear longitudinal model were performed at a relaxed threshold without multiple testing corrections. Additional pairwise comparisons were performed to find out the timepoint for the expression differences of specific miRNAs levels. The candidate variants from the first stage were then tested in the validation data set, and Bonferroni procedure was used to adjust the significance level for P values at each locus to control the overall false-positive rate at 0.05, considering the number of tested variants. Results were shown as the mean ± SD. For evaluation of sensitivity and specificity, a receiver operating characteristics (ROC) curve was used to determine cutoff points and to calculate the area under the curve (AUC) by using GraphPad PRISM 6.0.
RESULTS

MiRNAs Were Selectively Expressed in Pediatric LTxR Diagnosed With AR
The discovery pilot study contains a cohort of pediatric LTxR, including 14 AR, 7 BOS, and 13 stable. Within the AR group, miRNA levels were measured at AR (1 month), posttreatment for AR (6 months), and 1 year posttransplant. MiRNA levels in stable and BOS groups were measured at timepoints similar to those of AR patients at time of AR ( Figure 1A) . We selected 25 candidate miRNAs for pilot longitudinal study screening. The expression levels of miR-518f, let7b, let-7c, miR-548d, miR-369-5p, and miR-301a were too low to provide conclusive results. We used the remaining candidate miRNAs for our analysis. There was a significant downregulation of miR-10a, miR-195, and miR-133b levels and significant upregulation of miR-144, miR-142-5p, and miR-155 in serum from AR (1-month) compared to those after treatment of AR (6 months) and 1 year posttransplant (Figure 2 ). Other miRNAs were not significantly different over time in AR cohort, and all miRNAs levels showed no significant change over time in stable patients. These results, from our pilot discovery analysis, demonstrated that certain circulating miRNAs were differentially expressed in AR compared with those after treatment.
Pediatric LTxR Diagnosed With BOS Express Differential miRNAs Pattern
Expression levels of miR-134, miR-10a, miR-195, and miR-133b were significantly downregulated in the serum of FIGURE 1. Experiment design and work flow. A, Longitudinal study design in the pilot study of pediatric LTx patients. For the discovery pilot study, 14 AR, 7 BOS, and 13 stable patients were selected, and serum was collected at 1, 6, and 12 months after LTx. Within the AR group, all 14 patients developed AR in 1 month after LTx, and after treatment, there was no AR found after 6 and 12 months after LTx. There was no clinical diagnosis of BOS at 1 and 6 months in the 7 patients with BOS, whereas all these patients developed BOS at 12 months after LTx. All 13 stable patients maintained normal graft function at 1 year posttransplant. B, Statistical methods used in data analysis.
BOS LTxR at 12 months compared to those before BOS. In contrast, miR-144, miR-142-5p, and miR-155 showed significant upregulation in serum from BOS ( Figure 2 ). There was no significant differential expression in any miRNAs measured at 12 months after transplant between AR and stable. These results demonstrated that miRNAs in serum were selectively regulated in BOS patients after pediatric LTx. To validate our findings, we chose another independent set of both pediatric and adult LTxR who were either stable or diagnosed with AR or BOS.
Validation of Differential Serum miRNAs Using Pediatric and Adult Cohorts With AR
Another pediatric LTxR cohort including 6 AR, 7 BOS, and 8 stable was included for validation. In agreement with the pilot study, miR-10a, miR-195, and miR-133b levels were significantly lower (adjusted P < 0.05) in serum from AR when compared with stable. MiR-144, miR-142-5p, and miR-155 were significantly higher (adjusted P < 0.05) in AR compared with stable ( Figure 3 ). To determine whether miRNAs were differentially expressed in pediatric recipients undergoing rejection are also differently expressed in adult LTxR, 49 adult LTxR were enrolled, including 16 developed AR, 17 with BOS, and the other 16 stable. We found that miR-10a was significantly lower (adjusted P < 0.05) in AR compared with stable, whereas miR-144, miR-142-5p, and miR-155 were significantly higher (adjusted P < 0.05) (Figure 4 ). There was a trend for reduction of miR-195, miR-133b expression, but it is not significant.
Validation of Differential Serum miRNAs Using Pediatric and Adult Cohorts With BOS
MiR-134, miR-10a, miR-195, and miR-133b were significantly lower (adjusted P < 0.05) in the independent pediatric LTxR with BOS. Expression of miR-144, miR-142-5p, and miR-155 was significantly higher (adjusted P < 0.05) in BOS compared with stable ( Figure 3) . We further validated these miRNAs in the adult LTxR cohort. MiR-134, miR-10a, miR-195, and miR-133b were significantly lower (adjusted P < 0.05) in BOS compared with stable, whereas expression of miR-144, miR-142-5p, and miR-155 was higher (adjusted P < 0.05) in BOS (Figure 4 ). In addition, miR-144 demonstrated significantly higher expression levels in adult BOS patients compared with adult AR patients (Figure 4) , there was a trend of increased expression of miR-144 but without significant difference in pediatric LTxR between AR and BOS ( Figure 3 ). miR-134 was significantly downregulated in pediatric BOS patients compared with AR patients ( Figure 3) ; however, we did not see any differences in the expression of miR-134 in the adult patients (Figure 4 ). Further, a cutoff value for the expression of 0.7 for miR-134 could discriminate AR and BOS (P < 0.05) in pediatric patients both in the discovery analysis and validation cohort.
ROC Analysis of Circulating miRNAs Involved in AR
We performed a ROC analysis to calculate the relationship between sensitivity and specificity for combined pediatric LTxR cohorts (discovery and validation cohorts), 20 AR patients versus 21 stable patients. The ROC analysis showed that miR-142-5p, miR-155, and miR-195 could discriminate patients with AR from stable patients (miR-142-5p: AUC, 0.854; 95% confidence interval [CI], 0.718-0.99; sensitivity, 75%; specificity, 90.5%; miR-155: AUC, 0.876; 95% CI, 0.743-1.01; sensitivity, 81.2%; specificity, 85.7%; miR-195: AUC, 0.872; 95% CI, 0.738-1.005; sensitivity, 76.8%; specificity, 89.5%; P < 0.001 for all comparisons) ( Figure 5 and Table S4 ). We further combined multiple miRNAs together to test if the ROC improves, and that higher AUC was found when miR-155 and miR-195 were combined (AUC, 0.945; 95% CI, 0.893-1.095; sensitivity, 92.5%; specificity, 96.6%; P < 0.0001; Figure 5 and Table S4 ).
ROC Analysis of Circulating miRNAs Involved in BOS
Similarly, ROC curves were performed by comparing with pediatric patients with BOS versus stable allograft function (combined patients from discovery and validation cohorts) to evaluate the relationship between sensitivity and specificity for 7 differentially expressed miRNAs. MiR-10a, miR142- -144, -134, -10a, -195, -142-5p , -133b, and -155 was assessed by TaqMan RT-PCR on serum RNA samples from 13 stable LTxRs, 14 LTxRs with AR and 7 BOS LTxRs. Relative expression of these miRNAs was calculated and observed statistically differentially expressed compared to the stable group in 1 month. *P < 0.05, ** P < 0.01.
5p, miR-144, and miR-155 showed significant AUC values (miR-10a: AUC, 0.811; 95% CI, 0.688-0.954; sensitivity, 72%; specificity, 82%; miR-142-5p: AUC, 0.821; 95% CI, 0.723-0.988; sensitivity, 77%; specificity, 80%; miR-144: AUC, 0.85; 95% CI, 0.765-0.998; sensitivity, 86%; specificity, 85%; and miR-155: AUC, 0.808; 95% CI, 0.734-0.957; sensitivity, 78%; specificity, 82%; P < 0.001 for all comparisons; Figure 6 and Table S4 ). Further combination of multiple miRNAs for ROC analysis shown that miR-142-5p + miR-144 combined gave the highest AUC (AUC, 0.938; 95% CI, 0.882-1.079; sensitivity, 92%; specificity, 96%; P < 0.0001; Figure 6 and Table S4 , SDC, http://links. lww.com/TP/B380).
DISCUSSION
Dysregulated expression of miRNAs is associated with initiation and progression of pathological processes, including graft rejection. 19 We have previously reported miR-518f, -369-5p, -10a, -98, -548d, and -133b were differentially expressed in LTxR with BOS when compared with stable. 11 In the present study, we demonstrated that miR-10a, -195, -133b were significantly lower in pediatric LTxR with AR compared with those in stable and miR-144, -142-5p, -155 were significantly higher in AR. In addition, circulating levels of miR-134, -10a, -195, -133b (lower) and miR-144, -142-5p, -155 (higher) showed strong correlation with pediatric LTxR BOS (Figure 2) . We further validated these differential serum miRNAs using both pediatric and adult cohorts (Figures 3 and  4) . Therefore, our results demonstrate that circulating miRNAs were dysregulated in LTxR undergoing AR and BOS after LTx and may serve as potential noninvasive biomarkers of lung allograft rejection in pediatric lung transplant recipients.
Several of the miRNAs found in this report at a higher level in AR and BOS compared with stable have shown to play important roles in innate and adaptive immunities. For example, Relative expression of these miRNAs was calculated and observed statistically differentially expressed compared to the stable group. Bonferroni corrections were performed for adjustment to control false positive rate at 0.05, with consideration the number of tested variants. *P < 0.05, **P < 0.01. Relative expression of these miRNAs was calculated and observed statistically differentially expressed compared to the stable group. Bonferroni corrections were performed for adjustment to control false-positive rate at 0.05, with consideration the number of tested variants. *P < 0.05, **P < 0.01. miR-155 was upregulated in activated mouse macrophages and induce a broad range of inflammatory mediators. 27 Lind et al 28 demonstrated that there is increased expression of miR-155 after the activation of the T cell receptor and has been proposed to contribute in immunoglobulin class switching in B cells. In addition, evolutionarily conserved miR-155 plays an important role in regulating T helper cell differentiation and the germinal center formation to produce an optimal T cell-dependent antibody response. Our results demonstrating that miR-155 levels in the circulation was present in higher abundance in acute and chronic rejection compared with stable strongly suggest an important role for miR-155 in inducing an immune response directed against a transplanted organ. This is supported further by reports demonstrating that intragraft level of miR-142 was also higher in AR biopsies and renal transplant recipients with chronic antibody-mediated rejection when compared with stable renal allograft biopsies. 20 MiR-142 expression is mostly restricted to lymphoid cells and is expressed at a lower level in differentiated Th1 cells or Th2 cells compared with naive T cells. 29, 30 Our investigation showed miR-142-5p to be higher in AR and BOS, suggesting that upregulation of miR-142-5p in lymphoid cells is associated with acute and chronic rejection after LTx, though the underlying mechanisms remain unclear. Reduction of miRNA expression can result in the development of autoimmunity. 31 In LTxRs, we noted that circulating miR-10a, miR-195, and miR133b levels were significantly lower in patients diagnosed with BOS. MiR10a have been shown to be indispensable in vivo for global regulatory T (Treg) cell function under homeostatic conditions, 32 indicating that reduced miR-10a expression will inhibit Treg cell function, resulting in loss of peripheral tolerance leading to immune responses to lung associated self-antigens (SAgs) which has been proposed to play a role in BOS after LTx. MiR-195 was previously found to target regulatory factor X5 (RFX5) expression, 15 which can activate major histocompatibility complex class II members. Results presented here demonstrated that miR-195 was lower in the serum of LTxR with AR and BOS, demonstrating that dysregulated miR-195 in AR and BOS could participate in augmenting antigen presentation of donor allo-Ag as well as SAgs. Further, we have demonstrated the lower expression of circulating miR-133b in AR and BOS which is involved in IL-17 production in αβ and γδ T cells. 33 Alloimmunity evidenced by de novo development of antidonor MHC could also result in activation of Th17 responses leading to immune responses to lung associated SAgs (K-α1 Tubulin and Collagen V) and BOS. Therefore, miR-133b may exert a critical role for Th17 response and modulate the progression of alloimmunity-induced autoimmunity after LTx.
AR episodes have been shown to be an important risk factor for development of BOS after LTx. 14 The results presented with ROC curve demonstrated that circulating miRNAs (miR-155 and -195 together) can discriminate with greater than 96% specificity and 92% sensitivity between pediatric LTxR with AR and those without ( Figure 5 ). ROC analysis also demonstrated that miR-142-5p and -144 combinations can discriminate pediatric LTxR diagnosed with BOS from stable with greater than 92% sensitivity and 96% specificity ( Figure 6 ). Therefore, these results strongly suggest that circulating miRNAs will be of potential value as a diagnostic marker for the immune status of transplanted lungs.
There are several limitations in this study, mainly the sample size is small due to the fact that obtaining blood samples from pediatric patients is a challenge. Results have to be cross-sectionally validated in a larger sample-size cohort by using multivariable predictive models including potential confounding clinical variables. Furthermore, we did not perform any functional investigation of the identified miRNAs. Finally, we analyzed for selected miRNAs based on our earlier reports demonstrating association with acute and chronic rejection; therefore, at present, we cannot exclude other potentially relevant miRNAs which may be important for lung allograft rejection in children.
In summary, our study, for the first time, has defined selected miRNAs which are involved in immune regulation after pediatric LTxR. Target prediction and signal pathway analysis demonstrated that circulating miRNAs (miR-144, -134, -10a, -195, -142-5p, -133b, and -155) can be involved in regulating TGFβ signaling, T cell and B cell activation, Treg cell function, and Th17 activation as well as augmentation of both donor and SAg presentation by antigen-presenting cells. This selected panel of circulating miRNAs may also be useful as a potential noninvasive biomarker for diagnosis of lung allograft rejection.
